# KRASCENDO 3 (NCT07541170)

> A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07541170
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-small Cell Lung Cancer
- Interventions: Divarasib; Pembrolizumab; Nivolumab
- Enrollment: 400
- Primary outcome: Disease-free Survival (DFS), as Determined by the Investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=krascendo-3-nct07541170